CSF2 and breast cancer: Therefore, aggressive TNBC may suppress GM-CSF to support a protumor paracrine loop between mesenchymal-like BC cells and M2 macrophages, suggesting that TNBC patients may benefit from GM-CSF therapy, which is currently being tested in other BC subtypes45,46.